Fosamax Osteonecrosis of the Jaw Prognosis: Long term outcome of Osteonecrosis of the Jaw after Fosamax

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

Understanding Medication Safety and Long-Term Complications

The legacy of general health and science information has long emphasized the importance of understanding how medications interact with the body over time. In this broad context, the focus has often been on therapeutic benefits and common side effects, with less attention to rare, long-term complications that may emerge years after initial exposure. This foundational knowledge provides a framework for examining specific pharmaceutical agents and their potential delayed consequences. Within this heritage, bisphosphonates such as Fosamax have been widely prescribed for bone density management. As clinical experience accumulated, a rare but serious condition—osteonecrosis of the jaw—was identified in some patients. This finding shifted the discourse from general medication safety toward more targeted investigations of exposure duration, dosage, and individual susceptibility. The prognosis for affected individuals varies considerably, with outcomes depending on factors such as the extent of bone involvement and the timing of intervention.

From Clinical Observations to Occupational Considerations

This evolving understanding naturally extends to occupational settings where workers may encounter bisphosphonate compounds during manufacturing or handling. While patient-focused research has clarified risk factors for osteonecrosis of the jaw, the implications for workplace exposure remain less defined. The transition from clinical to occupational contexts requires careful consideration of how chronic, low-level contact with these substances might influence long-term health outcomes, particularly regarding jaw bone integrity. Fosamax (alendronate) is a bisphosphonate medication indicated for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its use, however, has been associated with a rare but serious adverse effect: osteonecrosis of the jaw (ONJ). ONJ is a condition characterized by exposed, non-healing bone in the maxillofacial region, which can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The condition has been reported in patients taking bisphosphonates, including Fosamax and Fosamax Plus D (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Prognosis and Long-Term Outcomes of ONJ After Fosamax

The prognosis for patients who develop ONJ after Fosamax exposure varies. According to the prescribing information, the time to onset of symptoms ranged from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients experienced relief of symptoms after discontinuing Fosamax, though a subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This suggests that while many patients can recover after cessation of the drug, the condition may be persistent or recurrent in some individuals, particularly if bisphosphonate therapy is resumed. Long-term outcome data from a large cohort study provide further insight. Among female patients treated for osteoporosis in the United Kingdom Clinical Practice Research Datalink, the risk of ONJ was threefold higher after 2-3 years of treatment and eightfold higher after 10 years, compared with past use (https://pubmed.ncbi.nlm.nih.gov/39400702/). However, absolute risks remained low, approximately 0.05% after 5 years, and diminished after discontinuation (https://pubmed.ncbi.nlm.nih.gov/39400702/). This indicates that the risk of ONJ increases with longer exposure to Fosamax, but the overall likelihood of developing the condition is small, and stopping the drug reduces future risk.

Risk Factors and Mechanisms

Several risk factors for ONJ have been identified. Known risk factors include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates, and for patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). These factors are important for clinicians to consider when assessing a patient's prognosis and management plan. The mechanistic pathways linking Fosamax to ONJ are not fully elucidated, but current research provides some understanding. A multiscale characterization of jawbone has provided comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). This suggests that the unique properties of the jawbone, such as its high turnover rate and blood supply, may make it particularly susceptible to the effects of bisphosphonates, which inhibit bone resorption. Over time, this inhibition may impair the normal healing processes, especially after dental trauma or infection, leading to necrotic bone exposure.

Warnings and Clinical Management

Regarding the adequacy of warnings, the prescribing information for Fosamax includes a specific section on osteonecrosis of the jaw, detailing its association with the drug, risk factors, and management recommendations (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56; https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The label advises discontinuation if severe symptoms develop and notes that most patients have relief after stopping (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, the label also states that in placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56), which may complicate risk communication. The timeline between exposure and documented harm can vary widely. Symptoms may appear as early as one day after starting Fosamax or may take several months to develop (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The risk increases with longer duration of use, with significant elevations seen after 2-3 years and especially after 10 years (https://pubmed.ncbi.nlm.nih.gov/39400702/). This delayed risk profile underscores the importance of periodic reassessment of the need for continued bisphosphonate therapy, as the optimal duration of use has not been determined, and for patients at low risk for fracture, drug discontinuation after 3 to 5 years may be considered (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the prognosis for osteonecrosis of the jaw after Fosamax use?

The prognosis is generally favorable for most patients upon drug discontinuation, with many experiencing relief of symptoms. However, the condition can be persistent or recurrent in some individuals, especially if bisphosphonate therapy is resumed. Long-term risks are low in absolute terms but increase with prolonged exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56; https://pubmed.ncbi.nlm.nih.gov/39400702/).

What are the risk factors for developing ONJ from Fosamax?

Known risk factors include invasive dental procedures, cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures. The risk increases with longer duration of bisphosphonate use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

How long does it take for ONJ symptoms to appear after starting Fosamax?

Symptoms may appear as early as one day after starting Fosamax or may take several months to develop. The risk increases with longer duration of use, with significant elevations after 2-3 years and especially after 10 years (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56; https://pubmed.ncbi.nlm.nih.gov/39400702/).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.